Page 143 - GPD-3-4

Gene & Protein in Disease A pyroptosis-related gene signature in myeloma

Author contributions 2022;97(8):1086-1107.

Conceptualization: Xinliang Mao, Yaner Wang doi: 10.1002/ajh.26590
Formal analysis: Yaner Wang, Qi Wang, Zhenqian Huang 8. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued
Investigation: Yaner Wang improvement in survival in multiple myeloma: Changes in
Writing–original draft: Yaner Wang, Xinliang Mao early mortality and outcomes in older patients. Leukemia.
Writing–review & editing: Yaner Wang, Xinliang Mao 2014;28(5):1122-1128.
Ethics approval and consent to participate doi: 10.1038/leu.2013.313
9. van de Donk N, Pawlyn C, Yong KL. Multiple myeloma.
Not applicable. Lancet. 2021;397(10272):410-427.
Consent for publication doi: 10.1016/S0140-6736(21)00135-5

Not applicable. 10. Farhana A, Lappin SL. Biochemistry, lactate dehydrogenase.
In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.
Availability of data 11. Liang JP, He YM, Cui YL, et al. Proteasomal inhibitors induce
The clinical data and PRGs for 859 MM patients were myeloma cell pyroptosis via the BAX/GSDME pathway. Acta
retrieved from The Cancer Genome Atlas (TCGA)- MMRF Pharmacol Sin. 2023;44(7):1464-1474.
CoMMpass project (https://portal.gdc.cancer.gov/ doi: 10.1038/s41401-023-01060-3
repository). In addition, the GTEx database was utilized 12. Jorgensen I, Miao EA. Pyroptotic cell death defends against
to analyze mRNA expression in the bone marrow of 70 intracellular pathogens. Immunol Rev. 2015;265(1):130-142.
healthy individuals, who served as the controls.
doi: 10.1111/imr.12287
References 13. Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by
1. Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, inflammatory caspases determines pyroptotic cell death.
risk-stratification, and management. Am J Hematol. Nature. 2015;526(7575):660-665.
2016;91(7):719-734. doi: 10.1038/nature15514
doi: 10.1002/ajh.24402 14. Chen X, He WT, Hu L, et al. Pyroptosis is driven by non-
2. Kazandjian D. Multiple myeloma epidemiology and survival: selective gasdermin-D pore and its morphology is different
A unique malignancy. Semin Oncol. 2016;43(6):676-681. from MLKL channel-mediated necroptosis. Cell Res.
2016;26(9):1007-1020.
doi: 10.1053/j.seminoncol.2016.11.004
doi: 10.1038/cr.2016.100
3. Palumbo A, Anderson K. Multiple myeloma. New Engl J
Med. 2011;364(11):1046-1060. 15. Ding J, Wang K, Liu W, et al. Pore-forming activity and
structural autoinhibition of the gasdermin family. Nature.
doi: 10.1056/NEJMra1011442 2016;535(7610):111-116.
4. Puig N, Paiva B, Lasa M, et al. Flow cytometry for fast doi: 10.1038/nature18590
screening and automated risk assessment in systemic light-
chain amyloidosis. Leukemia. 2019;33(5):1256-1267. 16. Li T, Zheng G, Li B, Tang L. Pyroptosis: A promising
therapeutic target for noninfectious diseases. Cell Prolif.
doi: 10.1038/s41375-018-0308-5
2021;54(11):e13137.
5. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, doi: 10.1111/cpr.13137
and dexamethasone with or without daratumumab before
and after autologous stem-cell transplantation for newly 17. Man SM. Inflammasomes in the gastrointestinal tract:
diagnosed multiple myeloma (CASSIOPEIA): A randomised, Infection, cancer and gut microbiota homeostasis. Nature
open-label, phase 3 study. Lancet. 2019;394(10192):29-38. Rev Gastroenterol Hepatol. 2018;15(12):721-737.
doi: 10.1016/s0140-6736(19)31240-1 doi: 10.1038/s41575-018-0054-1
6. Walker BA, Morgan GJ. The genomic features associated 18. Fang Y, Tian S, Pan Y, et al. Pyroptosis: A new frontier in
with high-risk multiple myeloma. Oncotarget. 2018;9(84): cancer. Biomed Pharmacother. 2020;121:109595.
35478-35479.
doi: 10.1016/j.biopha.2019.109595
doi: 10.18632/oncotarget.26269 19. Xia X, Wang X, Cheng Z, et al. The role of pyroptosis
7. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, in cancer: Pro-cancer or pro-“host”? Cell Death Dis.
risk stratification, and management. Am J Hematol. 2019;10(9):650.

Volume 3 Issue 4 (2024) 14 doi: 10.36922/gpd.4534